OnKure Therapeutics, Inc.
OKUR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001637715
In the last 90 days, OnKure Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 75 institutions reported holding it in 13F filings for Q2 2026, worth $159.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by OnKure Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $1.16K in total
- Insiders trading
- 2
- Net value
- −$1.16K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for OnKure Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Saccomano Nicholas A | President and CEO | 11,160 | Sep 23, 2026 | 6 |
| Leverone Jason A. | Chief Financial Officer | 18,500 | Sep 23, 2026 | 6 |
| Manke Isaac | Director | 20,583 | Aug 13, 2026 | 3 |
| Mathers Edward T | Director | 15,310 | Aug 11, 2026 | 4 |
| Ratcliffe Liam | Director | – | Aug 11, 2026 | 3 |
| Phillips Andrew John | Director | – | Aug 11, 2026 | 2 |
| Jansen Valerie Malyvanh | Director | – | Aug 11, 2026 | 2 |
| Grey Michael G | Director | 0 | Aug 11, 2026 | 2 |
| Carruthers R Michael | Director | 4,939 | Aug 11, 2026 | 2 |
| Hartley Dylan | Chief Scientific Officer | – | Aug 11, 2026 | 2 |
| Agresta Samuel | Chief Medical Officer | – | Aug 11, 2026 | 2 |
| Cormorant Asset Management, LP | Other: Former 10% Owner | 0Indirect | May 19, 2025 | 0 |
| Chen Bihua | Other: Former 10% Owner | 0Indirect | May 19, 2025 | 0 |
| Cormorant Global Healthcare Master Fund, LP | Other: Former 10% Owner | 0Indirect | May 19, 2025 | 0 |
| Cormorant Private Healthcare Fund III LP | Other: Former 10% Owner | 0Indirect | May 19, 2025 | 0 |
| Cormorant Private Healthcare Fund IV LP | Other: Former 10% Owner | 0Indirect | May 19, 2025 | 0 |
| Cormorant Private Healthcare Fund V LP | Other: Former 10% Owner | 0Indirect | May 19, 2025 | 0 |
| Hove Anders D | 10% Owner | 1,129,730Indirect | May 19, 2025 | 0 |
| Acorn Bioventures, L.P. | 10% Owner | 1,129,730Indirect | May 19, 2025 | 0 |
| Acorn Capital Advisors GP, LLC | 10% Owner | 1,129,730Indirect | May 19, 2025 | 0 |
| Leonard Braden Michael | Other: Former 10% owner of RPHM | 102,076 | Oct 9, 2024 | 0 |
| Hall Ashley | Chief Development Officer | 39,600 | Aug 29, 2023 | 0 |
| Novo Holdings A/S | 10% Owner | 3,330,337 | Jun 23, 2023 | 0 |
| Hoelscher Paul W. | Director | – | Jun 8, 2023 | 0 |
| Seltzer Stacey Denenberg | Director | – | Jun 8, 2023 | 0 |
| Dube Eric M | Director | – | Jun 8, 2023 | 0 |
| O'Donnell Niall | Director | 2,188,713Indirect | Jun 8, 2023 | 0 |
| Muralidhar Bali | Director | 2,073,957Indirect | Jun 8, 2023 | 0 |
| Blunt Roshawn A. | Director | – | Jun 8, 2023 | 0 |
| Dorenbaum Alejandro | Chief Medical Officer | 30,000 | Dec 13, 2022 | 0 |
| Flesher Gregory J. | President and CEO | 109,600 | Dec 13, 2022 | 0 |
| Cruse Michael | Chief Operating Officer | 13,697Indirect | Dec 13, 2022 | 0 |
| Lam Jennifer | VP of Finance & Administration | – | Dec 13, 2022 | 0 |
| Jindal Vineet R. | Chief Financial Officer | 36,600 | Dec 14, 2021 | 0 |
| Johnson Wendy S. | Chief Development Officer | 0 | Jul 15, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)4:54 PM ET | Sep 21 | 2 days | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −87 | $2.97 | −$258.76 | −0.8%11.2K after | |
| Sep 23, 2026 (view filing)4:52 PM ET | Sep 21 | 2 days | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −302 | $2.97 | −$898.21 | −1.6%18.5K after | |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −303 | $4.40 | −$1.33K | −1.6%18.8K after | |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −86 | $4.40 | −$378.4 | −0.8%11.2K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −301 | $4.16 | −$1.25K | −1.8%16.0K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −86 | $4.16 | −$357.76 | −1.2%7.33K after | |
| Dec 23, 2025 (view filing) | Dec 22 | 1 day | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −302 | $2.97 | −$896.94 | −1.8%16.3K after | |
| Dec 23, 2025 (view filing) | Dec 22 | 1 day | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −87 | $2.97 | −$258.39 | −1.2%7.42K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −303 | $2.62 | −$793.86 | −2.3%12.6K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −88 | $2.62 | −$230.56 | −2.4%3.51K after | |
| Jun 25, 2025 (view filing) | Jun 23 | 2 days | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −88 | $2.38 | −$209.44 | −2.4%3.59K after | |
| Jun 25, 2025 (view filing) | Jun 23 | 2 days | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −303 | $2.38 | −$721.14 | −2.3%12.9K after | |
| May 19, 2025 (view filing)5:33 PM ET | May 15 | 4 days | Cormorant Asset Management, LP and 5 othersOther: Former 10% Owner | SSaleClass A Common Stock | −1.81M | $1.85 | −$3.36M | −100.0%0 after | |
| May 19, 2025 (view filing)4:43 PM ET | May 15 | 4 days | Hove Anders D and 2 others10% Owner | PPurchase | +270.3K | $1.85 | +$500.0K | +18.8%1.71M after | |
| May 19, 2025 (view filing)4:43 PM ET | May 15 | 4 days | Hove Anders D and 2 others10% Owner | PPurchase | +1.13M | $1.85 | +$2.09M | New position1.13M after | |
| May 14, 2025 (view filing)4:36 PM ET | May 12 | 2 days | Cormorant Asset Management, LP and 5 others10% Owner | SSaleClass A Common Stock | −24.3K | $1.99 | −$48.2K | −1.3%1.81M after | |
| Apr 8, 2025 (view filing) | Apr 4-7 | 4 days | Saccomano Nicholas APresident and CEO | SSaleClass A Common Stock | −874 | $2.94 | −$2.57K | −19.2%3.68K after | 2 lots |
| Apr 8, 2025 (view filing) | Apr 4-7 | 4 days | Leverone Jason A.Chief Financial Officer | SSaleClass A Common Stock | −3.12K | $2.94 | −$9.18K | −19.1%13.2K after | 2 lots |
| Sep 26, 2024 (view filing) | Sep 24-25 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +98.3K | $1.47 | +$144.9K | +2.9%3.46M after | 2 lots |
| Sep 19, 2024 (view filing) | Sep 17-18 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +56.1K | $1.36 | +$76.3K | +1.7%3.36M after | 2 lots |
| Sep 16, 2024 (view filing) | Sep 12-16 | 4 days | Leonard Braden Michael10% Owner | PPurchase | +358.9K | $1.35 | +$483.8K | +12.2%3.30M after | 3 lots |
| Aug 14, 2024 (view filing) | Aug 13-14 | 1 day | Leonard Braden Michael10% Owner | PPurchase | +271.8K | $1.40 | +$379.8K | +10.2%2.94M after | 2 lots |
| May 16, 2024 (view filing) | May 14 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +414.3K | $1.54 | +$639.6K | +18.3%2.67M after | 2 lots |
| Aug 29, 2023 (view filing) | Aug 28 | 1 day | Hall AshleyChief Development Officer | SSale | −15.6K | $6.28 | −$98.1K | −28.3%39.6K after | |
| Jun 23, 2023 (view filing) | Jun 23 | Same day | Novo Holdings A/S10% Owner | SSale | −100.0K | $7.10 | −$710.0K | −2.9%3.33M after | |
| May 10, 2023 (view filing) | May 8 | 2 days | O'Donnell NiallDirector | PPurchase | +125.0K | $8.00 | +$1.00M | +6.1%2.19M after | |
| Sep 2, 2022 (view filing) | Sep 1 | 1 day | Cruse MichaelChief Operating Officer | PPurchase | +7.50K | $3.39 | +$25.4K | +121.0%13.7K after | |
| Aug 31, 2022 (view filing) | Aug 29-30 | 2 days | Cruse MichaelChief Operating Officer | PPurchase | +1.06K | $3.17 | +$3.35K | +3.4%31.8K after | 2 lots |
| Aug 31, 2022 (view filing) | Aug 29-31 | 2 days | Cruse MichaelChief Operating Officer | PPurchase | +6.20K | $3.21 | +$19.9K | New position6.20K after | 3 lots |
| Aug 26, 2021 (view filing) | Aug 25 | 1 day | Jindal Vineet R.Chief Financial Officer | PPurchase | +5.00K | $7.44 | +$37.2K | New position5.00K after | |
| Aug 26, 2021 (view filing) | Aug 25 | 1 day | Flesher Gregory J.President and CEO | PPurchase | +8.00K | $8.00 | +$64.0K | New position8.00K after | |
| Aug 26, 2021 (view filing) | Aug 25 | 1 day | Cruse MichaelSenior VP-Corporate Operations | PPurchase | +2.50K | $7.45 | +$18.6K | New position2.50K after | |
| Jul 15, 2021 (view filing) | Jul 14 | 1 day | Muralidhar BaliDirector | PPurchase | +111.7K | $8.50 | +$949.8K | +5.7%2.07M after | |
| Jul 15, 2021 (view filing) | Jul 14 | 1 day | Johnson Wendy S.Chief Development Officer | SSale | −111.7K | $8.50 | −$949.8K | −100.0%0 after |